Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III MultiCenter Randomized Controlled Study to Assess Efficacy and Safety of ON 01910.Na 72-Hr Continuous IV Infusion in MDS Patients With Excess Blasts Relapsing After or Refractory to or Intolerant to Azacitidine or Decitabine

NCT01241500 is registered in ClinicalTrials.gov with Traws Pharma, Inc. as lead sponsor.

NCT NCT01241500
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01241500 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III MultiCenter Randomized Controlled Study to Assess Efficacy and Safety of ON 01910.Na 72-Hr Continuous IV Infusion in MDS Patients With Excess Blasts Relapsing After or Refractory to or Intolerant to Azacitidine or Decitabine
Lead sponsor
Traws Pharma, Inc.
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2010
Completion date
October 3, 2018
Enrollment
299 (actual)
Sites
87

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myelomonocytic leukemia, mds, myelodysplastic syndromes, raeb